Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- AnGes MG’s CIN Therapeutic Vaccine Demonstrates Increased Efficacy in Combination with Kampo Medicine
April 24, 2013
- Merck Serono to Launch New Gonalef Pen Devices Starting in May
April 24, 2013
- Ibandronate Injection Non-Inferior to Risedronate: Chugai, Taisho
April 23, 2013
- Nichi-Iko to Launch Allegra AG in June, Says Identical with Original
April 23, 2013
- Daiichi Sankyo Launches Silodosin in China
April 23, 2013
- Ono Pharmaceutical Obtains Exclusive Rights for Once-Daily Wearing-Off Treatment
April 22, 2013
- Pfizer-Mylan Pair’s Japan Generic Share at 2.8%, Aspire for Bigger Slice of Market
April 22, 2013
- Taisho Files SGLT-2 Inhibitor Luseogliflozin, Submits RMP
April 22, 2013
- Merck Serono Obtains Marketing Rights for Cetrotide from Shionogi
April 22, 2013
- AnGes MG, Shionogi to Start PI Study for Nucleic Acid Drug for Atopic Dermatitis
April 19, 2013
- Daiichi Sankyo to Enter Branded Generics Business in Brazil with Launch of 2 Products
April 19, 2013
- Eli Lilly Japan Aims to Be a Top-10 Drug Maker in Japan by 2020, but Re-pricing and Generic Competition Could Pose Obstacles
April 19, 2013
- Tug-of-War over “Conflicts of Interest” (2): “Diovan Scandal” Brings Renewed Attention to COI
April 19, 2013
- Taisho, Nissui Launch Switch OTC Epadel; Prior Doctor Consultation Required for Patients
April 18, 2013
- Meiji Seika Pharma Licenses Schizophrenia Treatment from MSD, to Market It Independently
April 18, 2013
- Novo Nordisk Ups Efforts in Basal Insulin Market, Pits Tresiba against Lantus
April 18, 2013
- Pfizer’s Palbociclib Receives Breakthrough Therapy Designation from US FDA
April 18, 2013
- Teijin, Kyorin Expected to Grow thru “Win-Win” Relationship: Teijin Pharma Pres.
April 17, 2013
- Teijin Pharma Hopes to Derive 50%-Plus of Sales from New Drugs by around 2016: Pres. Uno
April 17, 2013
- BMKK Sales Up 13% to 62 Billion Yen in 2012
April 17, 2013
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…